Home » Stocks » XBIO

Xenetic Biosciences, Inc. (XBIO)

Stock Price: $4.07 USD -1.23 (-23.21%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $4.11 +0.04 (0.98%) Jul 30, 7:59 PM
Market Cap 35.60M
Revenue (ttm) 571,409
Net Income (ttm) -11.06M
Shares Out 8.75M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $4.07
Previous Close $5.30
Change ($) -1.23
Change (%) -23.21%
Day's Open 4.40
Day's Range 3.82 - 5.30
Day's Volume 18,392,753
52-Week Range 0.76 - 5.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

4 days ago - Accesswire

XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda's expansion news, it's looking at a big private sale.

6 days ago - InvestorPlace

Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other stocks mentioned: AZRX, CEMI
6 days ago - PennyStocks

FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

6 days ago - Accesswire

XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appe...

Other stocks mentioned: TAK
1 week ago - InvestorPlace

These penny stocks shot up substantially today; worth it or not? The post 3 Penny Stocks That Exploded Today, One Up 144% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other stocks mentioned: MDGS, MITQ
1 week ago - PennyStocks

Are these volatile penny stocks worth watching after big gains today? The post 3 Penny Stocks to Watch Making Big Gains Today, One Up 130% appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: AHPI, STRR
2 weeks ago - PennyStocks

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partn...

2 months ago - Accesswire

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...

2 months ago - Accesswire

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study wil...

4 months ago - Accesswire

Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging P...

4 months ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

4 months ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platf...

6 months ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platfo...

6 months ago - Accesswire

Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based com...

7 months ago - Benzinga

Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner PJSC Pharms...

7 months ago - Market Watch

The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) are trading at over 300% as it went from $1.08 in the previous close to $4.88 as of 11:17 AM ET. This is why it happened.

7 months ago - Pulse2

Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher. The post Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today ...

7 months ago - InvestorPlace

Nano-cap biotech Xenetic Biosciences Inc.'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying warrants.

2 years ago - Benzinga

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
XBIO
Full Company Profile

Financial Performance

In 2020, XBIO's revenue was $436,942, an increase of 2,460.31% compared to the previous year's $17,066. Losses were -$10.89 million, -14.73% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 22.85% from the latest price.

Price Target
$5.00
(22.85% upside)
Analyst Consensus: Buy